Who We Are
Precision Diabetes, Inc. (Raleigh, North Carolina) is an emerging leader in enabling precision medicine for diabetes through the use of novel diabetes biomarkers and algorithms. The company’s mission is to revolutionize the diagnostic assessment of diabetes by providing a spectrum of unique diabetes tests, spanning the risk of developing diabetes to developing diabetes complications. Precision Diabetes product portfolio includes several novel diabetes biomarkers and is the exclusive supplier of the GlycoMark test in the U.S., Europe, Australia, the Asia-Pacific Region, the Middle East, and Mexico. Precision Diabetes also has a partnership with Patia Europe to distribute a new type 2 diabetes genetic test, DIABETESpredict, and a genetic test for gestational diabetes, Matergen, in the United States.
DxGen Corp. and Precision Diabetes, Inc. Announce Strategic Partnership to Launch New Diabetes Point-Of-Care Testing Analyzer into the U.S. Market
1,5-anhydroglucitol Blood Test More Accurate than HbA1c and Glucose for Predicting Mortality COVID-19 Patients with and without Diabetes
New Late-Breaking Data at The American Diabetes Association Show GlycoMark® May Be an Effective Test for COVID-19 Severity
New Study Suggests GlycoMark® May Identify Highest Risk Patients with Prediabetes
Get in Touch
Precision Diabetes is located in Research Triangle Park (RTP), North Carolina. RTP is the largest research park in North America and is one of the most successful science parks across the globe.
Precision Diabetes, Inc.
1908 Eagle Creek Court
Raleigh, North Carolina 27606
1-888-744-0221 // 1-919-390-1391